• Policy
• Is Celltrion developing a combination of HBP?
• by Lee, Tak-Sun Nov 19, 2021 05:51am

• Policy
• Competition intensifies in Forsteo market with 4 latecomers
• by Lee, Tak-Sun Nov 19, 2021 05:51am

• Policy
• A law, proposed to prohibit overuse of drug price reduction
• by Lee, Jeong-Hwan Nov 19, 2021 05:51am

• Policy
• MFDS reviews emergency use of Merck’s oral COVID-19 pill
• by Lee, Tak-Sun Nov 18, 2021 05:54am

• Policy
• Major bills have been piled up
• by Lee, Jeong-Hwan Nov 18, 2021 05:54am

• Policy
• Will impurities again in losartan trigger full recalls?
• by Lee, Tak-Sun Nov 17, 2021 05:45am

• Policy
• No companies have won suits on Gov's price cut dispositions
• by Lee, Hye-Kyung Nov 16, 2021 05:53am

• Policy
• Chong Kun Dang is approved for its Jardiance Duo latecomer
• by Lee, Tak-Sun Nov 16, 2021 05:52am

• Policy
• Rx drugs,allowed according to CTD starting from next year
• by Lee, Tak-Sun Nov 15, 2021 05:56am

• Policy
• More convenient new dementia treatments introduced to market
• by Lee, Tak-Sun Nov 12, 2021 05:54am